Abstract: Systems and methods are described herein for facilitating use of artificial intelligence platforms to generate network mappings for conducting blockchain actions. The system may access an internal index for an artificial intelligence platform, wherein the internal index comprises on-chain self-executing program characteristics and off-chain self-executing program characteristics and wherein the on-chain self-executing program characteristics and off-chain self-executing program characteristics are archived in the internal index based on respective temporal identifiers.

Abstract: Systems and methods for a bifurcated self-executing program that wraps a first self-executing program (e.g., a first smart contract) on a blockchain within a second self-executing program (e.g., a second smart contract), in which the second self-executing program enforces the requirement for particular security credentials/certificates. The bifurcated self-executing program comprises a single compiled self-executing program that combines the first self-executing program and the second self-executing program.

Abstract: Systems and methods for generating shell-wrapped self-executing programs for conducting cryptographically secure blockchain actions on public, non-permissioned blockchain networks that are cryptographically secure. For example, the shell-wrapped self-executing program may comprise a shell program and the self-executing program. The shell program may contain and output one or more validation characteristics about the self-executing program and coupled data input systems (e.g., oracles) in response to a query about accessing the self-executing program. As such, any entity (e.g., a legacy computing system and/or another self-executing program) that requests to access the self-executing program may first receive information about the validation (if any) of the self-executing program.

Abstract: Systems and methods are described herein for facilitating use of artificial intelligence platforms to generate network mappings for conducting blockchain actions. The system may access an internal index for an artificial intelligence platform, wherein the internal index comprises on-chain self-executing program characteristics and off-chain self-executing program characteristics and wherein the on-chain self-executing program characteristics and off-chain self-executing program characteristics are archived in the internal index based on respective temporal identifiers.

Abstract: Various embodiments provide a homo-bivalent linker compound comprising identical functional groups at either end, methods of making such linker compounds, and methods of using the linker compounds.

Abstract: Systems and methods for a bifurcated self-executing program that wraps a first self-executing program (e.g., a first smart contract) on a blockchain within a second self-executing program (e.g., a second smart contract), in which the second self-executing program enforces the digital signature requirement. The bifurcated self-executing program comprises a single compiled self-executing program that combines the first self-executing program and the second self-executing program.

Abstract: Defined multi-conjugate oligonucleotides can have predetermined sizes and compositions. For example, in various embodiment, defined multi-conjugate oligonucleotides can have advantageous properties, for example in the form of defined multi-conjugate siRNA (i.e., including two, three or more siRNA) having enhanced intracellular delivery and/or multi-gene silencing effects. In various embodiment, the defined multi-conjugate oligonucleotides can be synthesized via new synthetic intermediates and methods. The defined multi-conjugate oligonucleotides can be used, for example, in reducing gene expression, biological research, treating or preventing medical conditions, or to produce new or altered phenotypes in cells or organisms.

Abstract: The present disclosure relates to multimeric oligonucleotides having monomeric subunits joined by linkers and methods of administering multimeric oligonucleotides to a subject. The multimeric oligonucleotides have a molecular weight and/or size configured to increase in vivo activity of one or more subunits within the multimeric oligonucleotide relative to in vivo activity of the same subunit when administered in monomeric form. The present disclosure also relates to such multimeric oligonucleotides and methods of synthesizing such multimeric oligonucleotides.

Abstract: Systems and methods for generating network mappings of self-executing program characteristics. For example, the system may receive a first user request to generate a mapping of a first network, wherein the mapping indicates self-executing program characteristics corresponding to each self-executing program of a first plurality of self-executing programs. In response to the first user request, the system may query the first plurality of self-executing programs to generate the mapping by identifying each self-executing program in the first plurality of self-executing programs, determining respective relationships between each self-executing program in the first plurality of self-executing programs and other self-executing programs in the first plurality of self-executing programs, and determining respective self-executing program characteristics for each self-executing program in the first plurality of self-executing programs. The system may store the mapping.

Abstract: Orthogonally linked multi-conjugates (such as multimeric oligonucleotides) are disclosed, along with methods of synthesizing them using orthogonal linking strategies to join together subunits that are biological moieties.

Abstract: The present disclosure relates to multimeric oligonucleotides comprising subunits, each of the subunits independently comprises a single-stranded or double-stranded oligonucleotide. Each of the subunits is joined to another subunit by a covalent linker, and at least one subunit comprises at least one partial single-stranded oligonucleotide. The present disclosure also relates to methods of synthesizing the multimeric oligonucleotides and the methods of using the multimeric oligonucleotides disclosed herein.

Abstract: A multi-conjugate comprising two or more covalently linked biological subunits, wherein at least two of the subunits are terminally located targeting ligands. A pharmaceutical composition comprising a pharmaceutically acceptable excipient and a therapeutic agent that is the multi-conjugate is also disclosed. The multi-conjugate may be administered to a subject for providing treatment or prophylaxis against a disease or other medical condition.

Abstract: Linker compounds, methods of making them, and methods of using them as linking agents for oligonucleotides and other chemical and biological substances are described. Embodiments of linker compounds are configured or selected to exhibit higher stability to cleavage by serum nucleases relative to intracellular nucleases, enabling enhanced control of longevity and hence bioavailability to a target cell of the chemical and biological substances linked together by such linker compounds when administered to a subject.

Abstract: Systems and methods for a bifurcated self-executing program that wraps a first self-executing program (e.g., a first smart contract) on a blockchain within a second self-executing program (e.g., a second smart contract), in which the second self-executing program enforces the requirement for particular security credentials/certificates. The bifurcated self-executing program comprises a single compiled self-executing program that combines the first self-executing program and the second self-executing program.

Abstract: The present disclosure relates to multimeric oligonucleotides comprising subunits, each of the subunits independently comprises a single-stranded or double-stranded oligonucleotide. Each of the subunits is joined to another subunit by a covalent linker, and at least one subunit comprises at least one partial single-stranded oligonucleotide. The present disclosure also relates to methods of synthesizing the multimeric oligonucleotides and the methods of using the multimeric oligonucleotides disclosed herein.

Abstract: Systems and methods for generating shell-wrapped self-executing programs for conducting cryptographically secure blockchain actions on public, non-permissioned blockchain networks that are cryptographically secure. For example, the shell-wrapped self-executing program may comprise a shell program and the self-executing program. The shell program may contain and output one or more validation characteristics about the self-executing program and coupled data input systems (e.g., oracles) in response to a query about accessing the self-executing program. As such, any entity (e.g., a legacy computing system and/or another self-executing program) that requests to access the self-executing program may first receive information about the validation (if any) of the self-executing program.

Abstract: The present disclosure relates to methods of administering, subcutaneously, to a subject, multimeric oligonucleotides having monomeric subunits joined by covalent linkers. The multimeric oligonucleotides have a molecular weight and/or size configured to increase in vivo activity of one or more subunits within the multimeric oligonucleotide relative to in vivo activity of the same subunit when administered in monomeric form of at least about 45 kD and other characteristics, such that their clearance due to glomerular filtration is reduced. The present disclosure also relates to such multimeric oligonucleotides and methods of synthesizing such multimeric oligonucleotides.

Abstract: Defined multi-conjugate oligonucleotides can have predetermined sizes and compositions. For example, in various embodiment, defined multi-conjugate oligonucleotides can have advantageous properties, for example in the form of defined multi-conjugate siRNA (i.e., including two, three or more siRNA) having enhanced intracellular delivery and/or multi-gene silencing effects. In various embodiment, the defined multi-conjugate oligonucleotides can be synthesized via new synthetic intermediates and methods. The defined multi-conjugate oligonucleotides can be used, for example, in reducing gene expression, biological research, treating or preventing medical conditions, or t9o produce new or altered phenotypes in cells or organisms.

Abstract: Defined multi-conjugate oligonucleotides can have predetermined sizes and compositions. For example, in various embodiment, defined multi-conjugate oligonucleotides can have advantageous properties, for example in the form of defined multi-conjugate siRNA (i.e., including two, three or more siRNA) having enhanced intracellular delivery and/or multi-gene silencing effects. In various embodiment, the defined multi-conjugate oligonucleotides can be synthesized via new synthetic intermediates and methods. The defined multi-conjugate oligonucleotides can be used, for example, in reducing gene expression, biological research, treating or preventing medical conditions, or to produce new or altered phenotypes in cells or organisms.

Abstract: Various embodiments provide a homo-bivalent covalent linker substituted on one end by a substituent X, wherein X comprises a biological moiety other than a nucleic acid.